AI‑driven drug developer Insilico Medicine struck commercial agreements splitting rights to its preclinical, brain‑penetrant NLRP3 inhibitor, generating upfront payments and structured milestones from regional partners. One announcement cited a $10 million upfront payment from a Chinese biotech as part of a broader ~$66 million rights‑split arrangement. A related transaction sees Hygtia Therapeutics (Fosun‑funded) license Insilico’s NLRP3 program for CNS indications, with Insilico retaining shared economic upside under co‑development or royalty terms. The deals illustrate a pragmatic approach by AI‑discovery companies to monetize preclinical assets through regional licensing while retaining exposure to global upside. Industry participants view the transactions as validation of computational discovery platforms and as a capital‑efficient route to de‑risk early assets ahead of clinical development.